Compounds > docetaxel anhydrous
Page last updated: 2024-09-04

docetaxel anhydrous and semaxinib

docetaxel anhydrous has been researched along with semaxinib in 2 studies

Compound Research Comparison

Studies
(docetaxel anhydrous)		Trials
(docetaxel anhydrous)		Recent Studies (post-2010)
(docetaxel anhydrous)		Studies
(semaxinib)		Trials
(semaxinib)		Recent Studies (post-2010) (semaxinib)
12,1103,2166,92048031218

Protein Interaction Comparison

ProteinTaxonomydocetaxel anhydrous (IC50)semaxinib (IC50)
Chain A, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RETHomo sapiens (human)0.17
Chain A, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RETHomo sapiens (human)0.17
Chain A, PROTO-ONCOGENE TYROSINE-PROTEIN KINASE RECEPTOR RETHomo sapiens (human)0.17
Dihydrofolate reductaseHomo sapiens (human)2.4
Dihydrofolate reductaseMus musculus (house mouse)2.4
Epidermal growth factor receptorHomo sapiens (human)3.592
Platelet-derived growth factor receptor betaMus musculus (house mouse)4.05
Macrophage colony-stimulating factor 1 receptorHomo sapiens (human)0.084
Proto-oncogene tyrosine-protein kinase receptor RetHomo sapiens (human)0.17
Neuronal acetylcholine receptor subunit alpha-4Rattus norvegicus (Norway rat)0.5
Platelet-derived growth factor receptor betaHomo sapiens (human)2.3563
Mast/stem cell growth factor receptor KitHomo sapiens (human)0.365
Fibroblast growth factor receptor 1Homo sapiens (human)4.865
Neuronal acetylcholine receptor subunit beta-2Rattus norvegicus (Norway rat)0.5
Proto-oncogene tyrosine-protein kinase SrcHomo sapiens (human)3.89
Dihydrofolate reductasePneumocystis carinii2.4
Platelet-derived growth factor receptor alphaHomo sapiens (human)0.2
Vascular endothelial growth factor receptor 1 Homo sapiens (human)0.7648
Fibroblast growth factor receptor 2Homo sapiens (human)5
Fibroblast growth factor receptor 4Homo sapiens (human)5
Fibroblast growth factor receptor 3Homo sapiens (human)5
Platelet-derived growth factor receptor alpha Mus musculus (house mouse)4.05
Vascular endothelial growth factor receptor 3Homo sapiens (human)0.275
Vascular endothelial growth factor receptor 2Mus musculus (house mouse)1.04
Vascular endothelial growth factor receptor 2Homo sapiens (human)1.0999
Vascular endothelial growth factor receptor 1Mus musculus (house mouse)1.04
Receptor-type tyrosine-protein kinase FLT3Homo sapiens (human)0.16
Mu-type opioid receptorCavia porcellus (domestic guinea pig)0.2
Vascular endothelial growth factor receptor 2Danio rerio (zebrafish)0.068
1,25-dihydroxyvitamin D-3 receptor Sus scrofa domesticus (domestic pig)1.04
Dihydrofolate reductaseRattus norvegicus (Norway rat)2.4
ALK tyrosine kinase receptorHomo sapiens (human)1.505

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (100.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Davis, MI; Khan, J; Li, SQ; Patel, PR; Shen, M; Sun, H; Thomas, CJ1
Bai, R; Bastian, A; Choudhary, S; Gangjee, A; Hamel, E; Ihnat, MA; Pavana, RK1

Other Studies

2 other study(ies) available for docetaxel anhydrous and semaxinib

ArticleYear
Identification of potent Yes1 kinase inhibitors using a library screening approach.
    Bioorganic & medicinal chemistry letters, 2013, Aug-01, Volume: 23, Issue:15

    Topics: Binding Sites; Cell Line; Cell Survival; Drug Design; Humans; Hydrogen Bonding; Molecular Docking Simulation; Protein Kinase Inhibitors; Protein Structure, Tertiary; Proto-Oncogene Proteins c-yes; Small Molecule Libraries; Structure-Activity Relationship

2013
Discovery and preclinical evaluation of 7-benzyl-N-(substituted)-pyrrolo[3,2-d]pyrimidin-4-amines as single agents with microtubule targeting effects along with triple-acting angiokinase inhibition as antitumor agents.
    Bioorganic & medicinal chemistry, 2017, 01-15, Volume: 25, Issue:2

    Topics: Angiogenesis Inhibitors; Antineoplastic Agents; Cell Line; Cell Proliferation; Dose-Response Relationship, Drug; Drug Discovery; Drug Screening Assays, Antitumor; Humans; Microtubules; Molecular Docking Simulation; Molecular Structure; Neovascularization, Pathologic; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Receptor Protein-Tyrosine Kinases; Structure-Activity Relationship

2017